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Survivala b s t r a c t
Background: This study aims to assess the effects of non-adherence to external beam radiation therapy in
cancer patients receiving treatment with a curative.
Methods: This retrospective cohort study collected health records data for all cancer patients treated with
external beam radiotherapy with curative intent in 2016 in Catalonia, Spain. Adherence was defined as
having received at least 90% of the total dose prescribed. A logistic regression model was used to assess
factors related to non-adherence, and its association with one-year survival was evaluated using Cox
regression.
Results: The final sample included 8721 patients (mean age 63.6 years): breast cancer was the most com-
mon tumour site (38.1%), followed by prostate and colon/rectum. Treatment interruptions prolonged the
total duration of therapy in 70.7% of the patients, and 1.0% were non-adherent. Non-adherence was asso-
ciated with advanced age, female gender, and some localization of primary tumour (head and neck, uri-
nary bladder, and haematological cancers). The risk of death in non-adherent patients was higher than in
adherent patients (hazard ratio [HR] 1.63, 95% confidence interval 0.97–2.74), after adjusting for the
potential confounding effect of age, gender, tumour site and comorbidity.
Conclusion: Non-adherence to radiotherapy, as measured by the received dose, is very low in our setting,
and it may have an impact on one-year survival.
 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 151 (2020) 200–205 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Adherence to chemotherapy and hormone therapy has proven
to be a relevant problem in cancer patients undergoing different
treatment regimens [1–3]. Adherence is defined as the degree to
which the patient’s behaviour is consistent with the therapy pre-
scribed by their doctor, and normally it is measured as the percent-
age of doses received relative to those indicated. The most typical
cutoff to define adherence in these terms is 80% [4]. In patients
with breast cancer, non-adherence is associated with a higher risk
of recurrence and death [5,6]. One literature review estimated the
proportion of patients with breast cancer who are adherent to hor-mone therapy during their first year of treatment at 79%, dropping
to 56% in the fifth year [7].
Radiotherapy differs from oral endocrine therapy and
chemotherapy in that it generally has a short duration (maximum
8 weeks) and entails regular medical and technical supervision
over the course of treatment. This context is favourable to high
adherence rates once the patient has agreed to undergo treatment.
As a result, assessing adherence has not been considered very rel-
evant in radiation oncology, and what research has been published
is oriented toward assessing interruptions (missed appointments
during the course of treatment) rather than evaluating adherence
in terms of receiving the prescribed doses [8,9].
Since the 1990s, the public healthcare system in Catalonia
(Spain) has maintained a registry of all patients receiving radio-
therapy with public financing. This study makes use of these data,
J.M. Borras et al. / Radiotherapy and Oncology 151 (2020) 200–205 201aiming to assess adherence to external radiotherapy measured by
the percentage of the total dose received in all cancer patients trea-
ted with radiotherapy and the impact on one-year survival.Material and methods
The initial cohort included all cancer patients indicated for
treatment with radiotherapy in 2016, provided they had received
at least one fraction of the prescribed treatment. We collected ret-
rospective data from the register of patients treated with external
beam radiotherapy in the 11 publicly funded radiation oncology
services in Catalonia. This represents about 90% of all patients
receiving radiation therapy in the region.
The variables included were: hospital, age, gender, tumour site
targeted, treatment indication (curative versus palliative), total
doses and sessions prescribed, final doses and sessions received,
date of treatment initiation and finalization, and treatment inter-
ruptions and their causes. The causes of interruption considered
included those related to the equipment (both unexpected break-
downs and planned maintenance); logistical challenges affecting
patients (usually transport); public holidays; medical problems
related to the patient (disease progression, intercurrent illness,
and/or treatment change); and personal reasons. It was possible
to consider more than one cause of treatment interruption in the
analysis. The minimum basic discharge data set was the source
of data to identify the comorbidity (Charlson Comorbidity Index)
of patients before starting radiotherapy treatment. Vital status
was ascertained from the Catalan Health Service database of
insured persons, which is updated monthly with the official mor-
tality statistics. For reasons of confidentiality, it was not possible
to obtain data on the specific cause of death.
The analysis was restricted to the patients receiving treatment
with a curative intent, defined from the standard prescribed ses-
sions according to tumour site. This number of sessions was estab-
lished for each tumour site; this definition allowed for some
patients with metastasis to be included in the cohort, but theseFig. 1. Flow charpatients were excluded from the analysis. We also excluded from
this analysis patients under the age of 18, those receiving only
brachytherapy, patients with treatment interruptions for medical
reasons (poor general condition due to treatment, disease progres-
sion, intercurrent illness, and/or treatment change), and those who
died within the first month of finishing treatment. We considered
these to be cases with an inappropriate indication for radiotherapy
with a curative intent.
Adherence was calculated as the percentage of doses received
relative to those prescribed. The cut-off was set at 90%, in agree-
ment with clinicians and taking into account the type of treatment
under study (short duration) and its therapeutic importance. In our
care context, the radiation oncology services have protocols in
place to calculate the necessary doses according to the service-
related, logistical, or schedule-related interruptions experienced,
and to extend the length of treatment in order to ensure that
patients receive at least the total doses prescribed. Patients who
did not receive 90% of the total dose due to non-medical reasons,
including patient-related ones, were considered non-adherent.
We performed a descriptive statistical analysis of the variables
and a multivariable logistic regression, using adherence as the out-
come variable and adjusting for hospital, age, gender, comorbidity
and tumour site. Results are expressed as odds ratios (OR) with
their 95% confidence intervals (CI). For the survival analysis, we
constructed a Kaplan-Meier curve and fit a Cox proportional haz-
ards model, adjusting for age, sex, hospital, comorbidity and the
diagnosis motivating the radiotherapy indication. All analyses
were undertaken using SPSS software (version 21).Results
Fig. 1 presents the patient selection flowchart. Of the 15,501
patients treated, 371 were excluded because they did not meet
the inclusion criteria, 5133 because they received radiotherapy
with a palliative intent, 728 because the patients stopped treat-
ment for medical reasons, 446 because they had metastasis andt of patients.
Table 1





Age (mean 63.6 ± 13.5 years)
49 years 1298 14.9
50–59 years 1843 21.1
60–69 years 2368 27.2
70–79 years 2250 25.8
80 years 962 11.0
Tumour site
Head and neck 714 8.2
Colorectal 798 9.2
Trachea, bronchus, lung 581 6.7
Skin 132 1.5
Breast 3322 38.1
Bones and connective tissues 129 1.5
Uterus 178 2.0
Prostate 1436 16.5
Urinary bladder 80 0.9
Central nervous system 303 3.5
Haematological 305 3.5
Cervix 132 1.5











Death at one year 824 9.8
Non-adherent 87 1.0
Total treatment interruptions due to: 6170 70.7
Equipment 3884 62.9
Personal reasons 297 4.8
Logistical reasons 805 13.0
Public holidays 5191 84.1
Days of treatment prolongation
2 days 2692 30.9
3–4 days 2509 28.8
5–7 days 2051 23.5
8–9 days 613 7.0
10 days 847 9.7
* Total number of cases N = 8721. The difference relative to the total N corre-
sponds to missing values.
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cohort was 8721 patients: 38.1% had breast cancer; 16.5%, prostate
cancer; and 9.2%, colorectal cancer. Smaller proportions had can-
cers of the head and neck, the lung, and other types.
Table 1 shows the patient characteristics. Over half were
women, and their mean age was 63.6 years. One per cent were
non-adherent. Treatment interruptions for any reason affected
70.7% of the patients with at least one missed appointment. Most
of the interruptions were related to equipment failures/mainte-
nance and public holidays. Just 4.8% of the treatments were inter-
rupted for personal reasons, while 13.0% of the interruptions were
for other reasons. Interruptions extended treatment duration by
more than two days in 69.1% of the cases (6020/8712). Also,
45.6% of de patients had no comorbidities.
Table 2 presents the factors related to non-adherence (less than
90% of the prescribed doses received). Women showed similar
adherence than men (OR 1.19 95% CI 0.63–2.24). Advanced age
appeared to confer a higher risk of non-adherence; however, nei-
ther the results for gender nor age were statistically significant.
Some diagnoses did show a significant association with non-
adherence, including tumours of the head and neck (OR 2.64 95%
CI 1.01–6.91). Patients with haematological cancers (OR 2.80 95%
CI 0.290–8.76) and cervical cancer (OR 2.08 95% CI 0.47–9.09) also
tended to be less adherent. On the other hand, patients with breast
and prostate cancers showed high levels of adherence. Non adher-
ence increased with number of comorbid pathologies, although
this association was not statistically significant.
Table 3 presents the results of the Cox model. After adjusting for
age, gender, hospital, comorbidity and diagnosis, there was a not
statistically significant difference in survival between patients
who did and did not receive at least 90% of the planned treatments.
Non-adherent patients had a higher risk of death at one year com-
pared to adherent ones (OR 1.63 95% CI 0.97–2.74). Fig. 2 shows
the survival curve according to adherence, as defined by percent-
age of the dose received (excluding patients who stopped treat-
ment for medical reasons). When the analysis focused on
patients who dropped out for exclusively personal reasons, the risk
of mortality was also double, although given the low volume of
cases (only 291 patient dropped out exclusively for patient-
related reasons) the results did not reach statistical significance
after adjusting for age, gender, tumour site and comorbidity (OR
1.88 95% CI 0.41–8.61).
Discussion
The proportion of patients who did not adhere to radiotherapy
(as measured by those not receiving a sufficient percentage of their
prescribed doses) was very low compared to that observed in
patients receiving other oncological treatments, like oral
chemotherapy or hormone therapy. Just 1.0% of all 8721 included
patients receiving radiotherapy with curative intent in 2016 in Cat-
alonia suspended their course of treatment before reaching 90% of
the total doses prescribed. When non-adherence was attributable
to non-medical reasons (progression of the disease, intercurrent
disease and/or change of therapy), it was associated with lower
one-year survival. This result clearly indicates that radiotherapy
is associated with high rates of adherence in our setting, thanks
in part to its short duration and the strict medical supervision
involved. Classically, shorter treatments are associated with a
lower risk of non-adherence [10].
This result implies two relevant corollaries: first, non-
adherence to radiotherapy is associated with an increased risk of
death in cancer patients receiving this therapy, and second, there
are some factors that can slightly increase the risk of non-
adherence, including advanced age and diagnosis of some tumour
types.Adherence is probably of special importance for tumour sites
such as the head and neck, bladder and cervix, as well as haemato-
logical cancers, which in our setting were all associated with a
higher risk of non-adherence. It is possible that these patients
dropped out of treatment for reasons that are not contemplated
in our study, for example socioeconomic determinants [11]. In
studies performed in populations with low socioeconomic status,
tumours of the cervix and the head and neck were also associated
with a greater risk of missed appointments in multivariable analy-
sis [8]. Elsewhere, too, head and neck cancers were associated with
a greater risk of missed appointments, as reported by Rangarajan in
India [12].
In radiation oncology, a large and consistent body of evidence
shows that treatment interruptions for any reason worsen the
patient’s prognosis [11,13–17]. This knowledge underpins the
notable efforts made to compensate interruptions with additional
fractions in order to administer at least the prescribed doses by
treatment end. The number of interruptions due to weekday public
holidays is very high in our country. This factor and others mean
Table 2
Prognostic and therapeutics factors associated with non-adherence.
Non-adherence
N (% Non-adherent) ORa (95% CI) p
Adherent 8595 1.0
Gender Men 3890 1.1 1
Women 4705 0.9 1.19 (0.63–2.24) 0.589
Age group 49 years 1285 1.1 1
50–59 years 1820 1.0 1.05 (0.51–2.16) 0.898
60–69 years 2327 0.6 0.61 (0.28–1.33) 0.212
70–79 years 2218 1.1 1.12 (0.54–2.36) 0.759
80 years 945 1.6 1.37 (0.61–3.07) 0.448
Tumour site Colorectal 784 0.8 1
Head and neck 695 2.3 2.64 (1.01–6.91) 0.048*
Trachea, bronchus, lung 570 1.1 1.35 (0.43–4.29) 0.609
Skin 130 2.3 2.42 (0.58–10.12) 0.225
Breast 3283 0.7 0.77 (0.28–2.09) 0.608
Bones & connective tissues 129 2.3 2.56 (0.60–10.86) 0.203
Uterus 172 1.2 1.13 (0.21–5.99) 0.888
Prostate 1418 0.8 1.10 (0.39–3.07) 0.863
Urinary bladder 79 3.8 4.69 (1.08–20.24) 0.039*
Central nervous system 293 0.7 0.70 (0.14–3.60) 0.671
Haematological 305 2.3 2.80 (0.90–8.76) 0.077
Cervix 132 2.3 2.08 (0.47–9.09) 0.333
Other digestive 324 0.0 - 0.994
Other 281 0.7 0.83 (0.16–4.22) 0.818
Comorbidities 0 3913 0.8 1
1–2 1733 1.2 1.30 (0.72–2.36) 0.380
3+ 424 1.7 1.71 (0.72–4.07) 0.224
Missing 2525 1.1 1.34 (0.80–2.25) 0.268
Interruptions No 2542 1.3 1
Yes 6053 0.9 1.32 (0.76–2.29) 0.323
Causes of interruption
Equipment No 2278 1.4 1
Yes 3775 0.6 0.58 (0.32–1.07) 0.081
Personal reasons No 5756 0.5 1
Yes 297 9.4 19.65 (10.19–37.87) <0.001*
Logistical reasons No 5248 0.9 1
Yes 805 1.1 1.79 (0.71–4.55) 0.219
Public holidays No 950 2.9 1
Yes 5103 0.5 0.19 (0.11–0.35) <0.001*
Death at one year No 7493 0.9 1
Yes 806 1.9 1.82 (0.96–3.44) 0.066
n (%): number of cases (% non-adherence); The difference relative to the total N corresponds to missing values.
ORa: odds ratio adjusted for centre, age group, gender, diagnosis, Comorbidities; CI: confidence interval.
* Statistical significance, P < 0.05.
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expected date, necessitating a substantial effort in clinical manage-
ment to complete the prescribed doses on time. The success of
these efforts is evidenced by the low number of patients who do
not receive their full dose once treatment has started. Thus, even
the patients whose treatment duration is extended by more than
two days have a high probability of finally receiving the totality
of the prescribed dose, with the subsequent benefits on their prog-
nosis. There is another option to cope with this problem, namely,
adding a second fraction on some treatment days, which was the
option chosen in 12.1% of the cases in our cohort. Another option
would be to work on Saturdays, as in other countries, which would
solve both problems (doses and overall treatment time), but this
option is not easily applicable in our health system due to manage-
ment criteria for organizing of delivery of radiation oncology.
These results also pose a problem related to measuring adher-
ence in radiation oncology, as practically all the published litera-
ture uses missed appointments, classified with criteria similar to
ours, to study this endpoint. In fact, even in a clinical trial per-
formed in patients with high-risk tumours, like those of the head
and neck, the probability of missed appointments was very high,
affecting up to 70% of the included patients. In an estimated12.7% of the cases, this kept patients from receiving their full dose,
and a quarter saw their treatment duration extended by more than
five days [18]. Thus, adherence can be conceived in two ways: as
missed appointments and as the proportion of doses received rel-
ative to those prescribed. With some exceptions [18], researchers
have focused on the former, analysing the dose received only in a
complementary way. In contrast, our study sheds light on the
impact of doses on the patient’s prognosis, which should be anal-
ysed independently from the prolongation of the treatment dura-
tion, even though its quantitative impact is limited. In that sense,
our proposal builds on Khalil’s work studying the impact of the
total dose lost as a necessary measure to complement the data
on missed appointments. Indeed, the effectiveness of the treatment
is a function of both the total doses administered and the treat-
ment time and fractioning.
Another aspect to highlight is that in this project, we made a
considerable effort to specify the causes of the treatment interrup-
tion. In some cases, treatments were interrupted for more than one
reason, and in our analysis, we excluded the patients whose treat-
ment was interrupted for medical reasons upon careful review by
the attending clinicians. We considered only patients who were
non-adherent for other reasons, and this decision could explain
Table 3
Cox regression for one-year survival.
Survival at one year of treatment end
n (% died) HRa (95% CI) p
Death at one year of treatment end 8299 9.7
Adherence Adherent 8216 9.6 1
Non-adherent 83 18.1 1.63 (0.97–2.74) 0.066
Gender Male 3808 14.2 1
Female 4608 6.2 0.93 (0.78–1.11) 0.416
Age group 49 years 1243 6.3 1
50–59 years 1775 7.0 1.06 (0.79–1.43) 0.690
60–69 years 2286 9.5 1.40 (1.06–1.85) 0.017*
70–79 years 2185 10.7 1.80 (1.36–2.38) <0.001*
80 years 927 18.6 2.64 (1.96–3.56) <0.001*
Tumour site Colorectal 765 6.5 1
Head and neck 681 18.9 3.40 (2.43–4.77) <0.001*
Trachea, bronchus, lung 561 32.3 5.44 (3.94–7.52) <0.001*
Skin 129 24.0 2.69 (1.69–4.28) <0.001*
Breast 3223 1.7 0.31 (0.20–0.47) <0.001*
Bones and connective tissues 124 14.5 2.59 (1.47–4.56) <0.001*
Uterus 170 5.9 0.79 (0.37–1.70) 0.551
Prostate 1397 1.3 0.17 (0.09–0.29) <0.001*
Urinary bladder 79 44.3 5.63 (3.59–8.82) <0.001*
Central nervous system 291 35.1 7.98(5.56–11.43) <0.001*
Haematological 286 8.7 1.50 (0.92–2.45) 0.104
Cervix 127 15.7 3.07 (1.79–5.27) <0.001*
Other digestive 311 33.4 6.25 (4.42–8.86) <0.001*
Other 272 16.5 2.70 (1.77–4.10) <0.001*
Comorbidities 0 3953 7.8 1
1–2 1763 14.7 1.15 (0.96–1.36) 0.128
3+ 431 21.3 1.35 (1.05–1.72) 0.017*
Missing 2269 7.3 0.90 (0.74–1.09) 0.273
n (%): number of cases (% of death patients at one year of treatment end).
The difference relative to the total N corresponds missing values.
HRa: hazard ratio adjusted for centre, age group, gender, diagnosis, comorbidities; CI: confidence interval.
*Statistical significance, P < 0.05.
Fig. 2. Overall survival by adherence.
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(1.0%) than other studies, for example, Khalil’s [18], who reported
that 12.7% of patients with head and neck cancer were non-
adherent.
Some limitations of this study should be mentioned. First, due
to reasons of confidentiality, it was not possible to ascertain the
cause of death, precluding an analysis of cause-specific survival,
which would have been more appropriate. Second, in 3.5% of the
cases it was not possible to ascertain the vital status at one year
after treatment. Third, although we adjusted for comorbidity, in
29.1% of the cases it was not possible to determine this information
prior to the radiation oncology treatment, so we opted to include
the patients with missing information for this variable as a cate-
gory in the multivariate analysis. Fourth, no data were available
on stage, either at diagnosis or before treatment initiation. Lastly,
we were not able to analyse some other variables of interest, such
as socioeconomic status or place of residence, which may be
important explanations for non-adherence.
One strength of this study is the fact that it is population-based
rather than limited to patients involved in a clinical trial for speci-
fic diagnoses. This approach minimized the selection bias, although
we did not included the estimated 10% of patients receiving treat-
ment in private facilities. The definition of the study population as
cases treated with a curative intent, and the detailed definition of
the causes of treatment interruption, are other relevant aspects,
as is the review of dubious cases by clinicians. Also, the small per-
centage of cases with metastasis at the start of treatment were
excluded, even though treatment intent was defined as curative,
to minimize bias. Palliative indications could likewise have influ-
enced non-adherence, possibly reducing it further due to shorter
treatments [19], although these patients have limited survival
time, which would have made it very difficult to pool these
patients in an analysis of those treated with curative intent due
to the different aims of the therapy.
Radiation oncology is a basic pillar of multidisciplinary cancer
treatment, and it contributes independently to local disease con-
trol and overall survival [20]. It is necessary to measure non-
adherence based on total doses received relative to prescribed
doses, not just based on missed appointments. The percentage of
non-adherent patients is very low (1.0%) according to the dose
received, whereas 70.7% of the treatments had interruptions due
to weekday public holidays, machine malfunctions, equipment
maintenance, and personal reasons. Considering the quantity of
interruptions due to public holidays, expanding services to Satur-
days should be considered, as this could minimize the impact on
the patient and allow compensation for total doses and treatment
time. Overall, non-adherence may have a relevant impact on the
prognosis of oncological diseases, and professionals should moni-
tor it during the course of treatment.Conflicts of interest
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